Innoviva (INVA) Stock Forecast & Price Target

Innoviva is supported by a durable, high-margin royalty engine from Breo and Anoro, with meaningful royalty rights that are estimated to generate about $1.0B in royalty revenue over the next five years and largely flow to the bottom line, while those inhaled therapies are also viewed as de-risked by drug-class and geographic diversification. Its outlook is further strengthened by an expanding operating platform in infectious disease and critical care, where internally marketed products exceeded $180M in LTM revenue as of March 2026 and grew 37% y/y in 1Q26, helped by $51.8M in WW product sales and an approximate $4M milestone from Zai Lab tied to XacDuro. On top of that core cash generation, Innoviva has multiple optionality catalysts from strategic assets and acquisitions, including a 68% stake in Armata, the potential 2H26 commercialization of zoliflodacin, and management’s openness to 20 to 30 acquisition opportunities, which together create a compelling mix of recurring earnings, growth, and capital deployment upside.

Innoviva is facing a fundamentally mixed but increasingly fragile earnings profile because its royalty business weakened to $59.8M, down 11% year over year, as GSK cited pricing pressure in the U.S. and softer demand in inhaled respiratory markets, prompting longer-term royalty revenue estimates to be cut by 4% to 9%. Although the IST platform is still growing, with U.S. IST product revenue up 26% year over year to $36.6M on Giapreza and XacDuro strength, the broader portfolio remains reliant on a small number of products and the outlook for Zevtera has deteriorated sharply, with expected peak sales reduced from about $72M to $39M in 2033E amid flattish sales of roughly $0.4M. Innoviva also depends on milestone-driven revenue that can be lumpy, as shown by the $11.5M in license and other revenue driven by one-time payments from Zai Lab, Dr. Reddy's, and GARDP, which highlights that the company’s reported growth is not yet fully supported by durable, broad-based commercial traction.